Latitude Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
CI
APM
HIIFS
Latitude Advisors's XBI Position: Q2 2022 in Review
Latitude Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 6,004 shares — an estimated $540K sold.
Latitude Advisors first reported a position in XBI in Q4 2020 and held it in 6 quarters. The position peaked at $540K in Q1 2022. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.
- Latitude Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
- Latitude Advisors sold 6,004 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $540K.
- Latitude Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and held it in 6 quarters.
- Latitude Advisors's State Street SPDR S&P Biotech ETF position peaked at $540K in Q1 2022.
- 706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.
Based on Latitude Advisors's 13F filing for Q2 2022, filed 28 Jul 2022.